Bionomics Presentations & Investor Relations material

Bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. Our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. This portfolio is fed by highly productive drug discovery platforms which includes MultiCore®, our proprietary chemistry capability. At the core of our business is strategic partnering. We partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. This means we can focus our strengths in innovative drug discovery to extract as many 'shots on goal'​ from our diverse pipeline in the quest to create the world's new blockbuster drugs. We have a passion for what we do and we work with the best in the world to deliver meaningful outcomes from our discoveries. We look forward to you accompanying us on this extremely valuable journey. You can learn more about our story at in Adelaide, Australia, with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.